Rapid screening for entry inhibitors of highly pathogenic viruses under low-level biocontainment

Aparna Talekar, Antonello Pessi, Fraser Glickman, Uttara Sengupta, Thomas Briese, Michael Whitt, Cyrille Mathieu, Branka Horvat, Anne Moscona, Matteo Porotto

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Emerging viruses including Nipah, Hendra, Lujo, and Junin viruses have enormous potential to spread rapidly. Nipah virus, after emerging as a zoonosis, has also evolved the capacity for human-to-human transmission. Most of the diseases caused by these pathogens are untreatable and require high biocontainment conditions. Universal methods for rapidly identifying and screening candidate antivirals are urgently needed. We have developed a modular antiviral platform strategy that relies on simple bioinformatic and genetic information about each pathogen. Central to this platform is the use of envelope glycoprotein cDNAs to establish multi-cycle replication systems under BSL2 conditions for viral pathogens that normally require BSL3 and BSL4 facilities. We generated monoclonal antibodies against Nipah G by cDNA immunization in rats, and we showed that these antibodies neutralize both Nipah and Hendra live viruses. We then used these effective Henipavirus inhibitors to validate our screening strategy. Our proposed strategy should contribute to the response capability for emerging infectious diseases, providing a way to initiate antiviral development immediately upon identifying novel viruses.

Original languageEnglish (US)
Article numbere30538
JournalPLoS One
Volume7
Issue number3
DOIs
StatePublished - Mar 2 2012

Fingerprint

biocontainment
Hendra Virus
Nipah Virus
Nipah virus
Viruses
Antiviral Agents
Screening
Lujo virus
screening
Pathogens
viruses
pathogens
Henipavirus
Junin virus
Hendra virus
Complementary DNA
Emerging Communicable Diseases
emerging diseases
Zoonoses
zoonoses

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Talekar, A., Pessi, A., Glickman, F., Sengupta, U., Briese, T., Whitt, M., ... Porotto, M. (2012). Rapid screening for entry inhibitors of highly pathogenic viruses under low-level biocontainment. PLoS One, 7(3), [e30538]. https://doi.org/10.1371/journal.pone.0030538

Rapid screening for entry inhibitors of highly pathogenic viruses under low-level biocontainment. / Talekar, Aparna; Pessi, Antonello; Glickman, Fraser; Sengupta, Uttara; Briese, Thomas; Whitt, Michael; Mathieu, Cyrille; Horvat, Branka; Moscona, Anne; Porotto, Matteo.

In: PLoS One, Vol. 7, No. 3, e30538, 02.03.2012.

Research output: Contribution to journalArticle

Talekar, A, Pessi, A, Glickman, F, Sengupta, U, Briese, T, Whitt, M, Mathieu, C, Horvat, B, Moscona, A & Porotto, M 2012, 'Rapid screening for entry inhibitors of highly pathogenic viruses under low-level biocontainment', PLoS One, vol. 7, no. 3, e30538. https://doi.org/10.1371/journal.pone.0030538
Talekar, Aparna ; Pessi, Antonello ; Glickman, Fraser ; Sengupta, Uttara ; Briese, Thomas ; Whitt, Michael ; Mathieu, Cyrille ; Horvat, Branka ; Moscona, Anne ; Porotto, Matteo. / Rapid screening for entry inhibitors of highly pathogenic viruses under low-level biocontainment. In: PLoS One. 2012 ; Vol. 7, No. 3.
@article{17fdc9c0e615427e8ccf154c5185d816,
title = "Rapid screening for entry inhibitors of highly pathogenic viruses under low-level biocontainment",
abstract = "Emerging viruses including Nipah, Hendra, Lujo, and Junin viruses have enormous potential to spread rapidly. Nipah virus, after emerging as a zoonosis, has also evolved the capacity for human-to-human transmission. Most of the diseases caused by these pathogens are untreatable and require high biocontainment conditions. Universal methods for rapidly identifying and screening candidate antivirals are urgently needed. We have developed a modular antiviral platform strategy that relies on simple bioinformatic and genetic information about each pathogen. Central to this platform is the use of envelope glycoprotein cDNAs to establish multi-cycle replication systems under BSL2 conditions for viral pathogens that normally require BSL3 and BSL4 facilities. We generated monoclonal antibodies against Nipah G by cDNA immunization in rats, and we showed that these antibodies neutralize both Nipah and Hendra live viruses. We then used these effective Henipavirus inhibitors to validate our screening strategy. Our proposed strategy should contribute to the response capability for emerging infectious diseases, providing a way to initiate antiviral development immediately upon identifying novel viruses.",
author = "Aparna Talekar and Antonello Pessi and Fraser Glickman and Uttara Sengupta and Thomas Briese and Michael Whitt and Cyrille Mathieu and Branka Horvat and Anne Moscona and Matteo Porotto",
year = "2012",
month = "3",
day = "2",
doi = "10.1371/journal.pone.0030538",
language = "English (US)",
volume = "7",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "3",

}

TY - JOUR

T1 - Rapid screening for entry inhibitors of highly pathogenic viruses under low-level biocontainment

AU - Talekar, Aparna

AU - Pessi, Antonello

AU - Glickman, Fraser

AU - Sengupta, Uttara

AU - Briese, Thomas

AU - Whitt, Michael

AU - Mathieu, Cyrille

AU - Horvat, Branka

AU - Moscona, Anne

AU - Porotto, Matteo

PY - 2012/3/2

Y1 - 2012/3/2

N2 - Emerging viruses including Nipah, Hendra, Lujo, and Junin viruses have enormous potential to spread rapidly. Nipah virus, after emerging as a zoonosis, has also evolved the capacity for human-to-human transmission. Most of the diseases caused by these pathogens are untreatable and require high biocontainment conditions. Universal methods for rapidly identifying and screening candidate antivirals are urgently needed. We have developed a modular antiviral platform strategy that relies on simple bioinformatic and genetic information about each pathogen. Central to this platform is the use of envelope glycoprotein cDNAs to establish multi-cycle replication systems under BSL2 conditions for viral pathogens that normally require BSL3 and BSL4 facilities. We generated monoclonal antibodies against Nipah G by cDNA immunization in rats, and we showed that these antibodies neutralize both Nipah and Hendra live viruses. We then used these effective Henipavirus inhibitors to validate our screening strategy. Our proposed strategy should contribute to the response capability for emerging infectious diseases, providing a way to initiate antiviral development immediately upon identifying novel viruses.

AB - Emerging viruses including Nipah, Hendra, Lujo, and Junin viruses have enormous potential to spread rapidly. Nipah virus, after emerging as a zoonosis, has also evolved the capacity for human-to-human transmission. Most of the diseases caused by these pathogens are untreatable and require high biocontainment conditions. Universal methods for rapidly identifying and screening candidate antivirals are urgently needed. We have developed a modular antiviral platform strategy that relies on simple bioinformatic and genetic information about each pathogen. Central to this platform is the use of envelope glycoprotein cDNAs to establish multi-cycle replication systems under BSL2 conditions for viral pathogens that normally require BSL3 and BSL4 facilities. We generated monoclonal antibodies against Nipah G by cDNA immunization in rats, and we showed that these antibodies neutralize both Nipah and Hendra live viruses. We then used these effective Henipavirus inhibitors to validate our screening strategy. Our proposed strategy should contribute to the response capability for emerging infectious diseases, providing a way to initiate antiviral development immediately upon identifying novel viruses.

UR - http://www.scopus.com/inward/record.url?scp=84857707719&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857707719&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0030538

DO - 10.1371/journal.pone.0030538

M3 - Article

VL - 7

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 3

M1 - e30538

ER -